Literature DB >> 34029268

EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases.

Jia-Li Yuan1, Cheng-Ye Yin, Ying-Ze Li, Shuai Song, Guo-Jian Fang, Qun-Shan Wang.   

Abstract

ABSTRACT: Enhancer of zeste homolog 2(EZH2) is an enzymatic subunit of polycomb repressive complex 2 (PRC2) and is responsible for catalyzing mono-, di-, and trimethylation of histone H3 at lysine-27(H3K27me1/2/3). Many noncoding RNAs or signaling pathways are involved in EZH2 functional alterations. This new epigenetic regulation of target genes is able to silence downstream gene expression and modify physiological and pathological processes in heart development, cardiomyocyte regeneration, and cardiovascular diseases, such as hypertrophy, ischemic heart diseases, atherosclerosis, and cardiac fibrosis. Targeting the function of EZH2 could be a potential therapeutic approach for cardiovascular diseases.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34029268     DOI: 10.1097/FJC.0000000000001062

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Astronauts Plasma-Derived Exosomes Induced Aberrant EZH2-Mediated H3K27me3 Epigenetic Regulation of the Vitamin D Receptor.

Authors:  Malik Bisserier; Agnieszka Brojakowska; Nathaniel Saffran; Amit Kumar Rai; Brooke Lee; Matthew Coleman; Aimy Sebastian; Angela Evans; Paul J Mills; Sankar Addya; Arsen Arakelyan; Venkata Naga Srikanth Garikipati; Lahouaria Hadri; David A Goukassian
Journal:  Front Cardiovasc Med       Date:  2022-06-16

Review 2.  Long Non-Coding RNA Regulation of Epigenetics in Vascular Cells.

Authors:  Hester Garratt; Robert Ashburn; Miron Sopić; Antonella Nogara; Andrea Caporali; Tijana Mitić
Journal:  Noncoding RNA       Date:  2021-09-23

Review 3.  Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis.

Authors:  Jingrong Shao; Jiao Liu; Shengkai Zuo
Journal:  Cells       Date:  2022-07-30       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.